A phase I study to determine the safety and pharmacokinetics of BMS-387032 [SNS 032] given every three weeks in patients with metastatic refractory solid tumors-CNS
Phase of Trial: Phase I
Latest Information Update: 26 Jun 2007
At a glance
- Drugs SNS 032 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 26 Jun 2007 New trial record.